SinoMab BioScience Limited (HKG:3681)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.760
-0.010 (-0.56%)
At close: Mar 27, 2026
Market Cap2.44B +91.1%
Revenue (ttm)n/a
Net Income-116.83M
EPS-0.10
Shares Out1.39B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,706,100
Average Volume4,295,055
Open1.800
Previous Close1.770
Day's Range1.720 - 1.850
52-Week Range1.050 - 3.760
Beta0.61
RSI47.64
Earnings DateMar 23, 2026

About SinoMab BioScience

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 61
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3681
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements